NCT02368080已完成不适用
Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Adults: a Comparison of Two Commercially Available Devices
Cliniques universitaires Saint-Luc- Université Catholique de Louvain1 个研究点 分布在 1 个国家目标入组 95 人开始时间: 2013年4月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 95
- 试验地点
- 1
- 主要终点
- Lung Clearance Index (LCI)
研究概览
简要总结
This study compares the lung clearance index (LCI) in cystic fibrosis and healthy adults obtained with two different multiple breath nitrogen washout (MBWN2) devices. Each participants will perform the test (LCI) in duplicate on each device.
详细描述
Using nitrogen as the inert gas, there are currently two commercially available devices that offer the possibility to measure the LCI. However, comparison between them are lacking. The 2 MBWN2 devices are the "EasyOne Pro Lab" (ndd Medical Technologies, Zürich, Switzerland) and the "Exhalyzer D" (Eco Medics AG, Duernten, Switzerland).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Cystic fibrosis diagnosis
排除标准
- •Respiratory infection within 3 weeks
- •Chronically infected with methicillin-resistant Staphylococcus aureus or Burkholderia Cepacia
结局指标
主要结局
Lung Clearance Index (LCI)
时间窗: 1 hour
次要结局
- Functional residual capacity (FRC) ( the helium rebreathing technique (FRC He) with a "Jaeger Masterscreen" (Würzburg, Germany)(1 hour)
- Discriminative ability of LCI of each device (assessed by evaluating the proportion of patients with normal spirometry but high LCI with each device)(1 hour)
研究者
Poncin
Physiotherapist
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis ChildrenHealthyCystic FibrosisNCT02378454Cliniques universitaires Saint-Luc- Université Catholique de Louvain100
已完成
不适用
Retrospective Observational Study to Compare Cystic Fibrosis Patients in Two Decades Before and After 2000Cystic FibrosisNCT01651455Chiesi Farmaceutici S.p.A.92
已完成
3 期
Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa InfectionsPseudomonas Aeruginosa InfectionNCT01315678Insmed Incorporated302
撤回
3 期
Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas AeruginosaCystic FibrosisNCT01315691Insmed Incorporated
已完成
不适用
Non-Invasive Biomarkers in Cystic FibrosisCystic FibrosisNCT00413140Maastricht University Medical Center100